Find XO: KONEXT Secures 15 Billion KRW, Pharmarise Becomes Shareholder (venturesquare.net)

- Pharmarise joined KONEXT's 15 billion KRW Series C investment as a strategic investor. - For bio founders, the point of interest is securing a partner who can support from clinical trials to commercialization, along with the investment amount. - However, merely participating in the investment does not necessarily accelerate the development schedule; clear agreements on who takes on what tasks and by when are necessary to expect support beyond funding in actual collaboration.